Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities
about
How we treat chronic active Epstein-Barr virus infection.TCR-like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus-transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants.Combination of betulinic acid and chidamide synergistically inhibits Epstein-Barr virus replication through over-generation of reactive oxygen species.TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
P2860
Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting Epstein-Barr virus-t ...... ll receptor-like specificities
@en
Targeting Epstein-Barr virus-t ...... l receptor-like specificities.
@nl
type
label
Targeting Epstein-Barr virus-t ...... ll receptor-like specificities
@en
Targeting Epstein-Barr virus-t ...... l receptor-like specificities.
@nl
prefLabel
Targeting Epstein-Barr virus-t ...... ll receptor-like specificities
@en
Targeting Epstein-Barr virus-t ...... l receptor-like specificities.
@nl
P2093
P2860
P1433
P1476
Targeting Epstein-Barr virus-t ...... ll receptor-like specificities
@en
P2093
Angeline Pei Chiew Lim
Brendon J Hanson
Chien Tei Too
Fatimah Bte Mustafa
Jianzhu Chen
Joanna Ai Ling Choo
Junyun Lai
Lan Hiong Wong
Nalini Srinivasan
Paul A MacAry
P2860
P304
P356
10.1182/BLOOD-2016-03-707836
P407
P577
2016-06-23T00:00:00Z